Ranit D'rozario

Ghaziabad, UP, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis.

Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis.

Journal: European journal of immunology

Published: July 04, 2025

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

Journal: Nature communications

Published: June 18, 2025

Piezo1 mechanosensing regulates integrin-dependent chemotactic migration in human T cells.

Piezo1 mechanosensing regulates integrin-dependent chemotactic migration in human T cells.

Journal: eLife

Published: February 23, 2024

Cutting Edge: ATP13A2 Is an Endolysosomal Regulator of TLR9/7 Activation in Human Plasmacytoid Dendritic Cells.

Cutting Edge: ATP13A2 Is an Endolysosomal Regulator of TLR9/7 Activation in Human Plasmacytoid Dendritic Cells.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 03, 2023

Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study.

Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study.

Journal: Life science alliance

Published: August 03, 2023

Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19.

Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19.

Journal: Gut pathogens

Published: November 21, 2022

Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19.

Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19.

Journal: Viruses

Published: November 01, 2022

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes

Published: September 19, 2022

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.

Journal: Frontiers in immunology

Published: July 08, 2021

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.

Journal: Nature communications

Published: February 19, 2021

Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19.

Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19.

Journal: The Journal of infectious diseases

Published: November 03, 2020

Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells.

Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells.

Journal: Frontiers in immunology

Published: May 01, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026